Novo Nordisk, manufacturer of Ozempic and Wegovy, has announced that it will cut about 11% of its global workforce to save 8 billion Danish crowns (US $ 1.3 billion) by the end of 2026, according to a statement released on Wednesday, 10. In total, approximately 9,000 positions in the company currently, with 5,000 jobs in the company, will be eliminated in the company. Denmark.
The multinational pharmacist attributed the decision to the need to increase the speed of transformation and redirect resources to expand its portfolio of drugs for diabetes and obesity.
On the other hand, Novo Nordisk expects a negative impact of 6 percentage points on this year’s operating profit, designed between 4% to 10%. At Guidance issued in August, the company expected discharge in operational profit between 10% to 16% in 2025.
The next new financial results of the new Nordisk will be released on November 5, with the figures for the first nine months of this year.
After the announcement, the action of the new Nordisk climbed 3.4% in Copenhagen, around 8:20 am (Brasília).
